INS and obesity due to melanocortin 4 receptor deficiency: These include T2DM patients who cannot adequately control their diabetes with oral therapy, and who have considerable obesity, or where hypoglycaemia and/or weight gain is particularly problematic or for whom therapy with insulin would have significant occupational implications.